Indefinite Delivery Contract SPE2DR25D1110

Award Date 8/1/25
Last Date to Order 12/31/36
Ultimate Awardee
Not listed
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Single
Primary Consortia Member
Not listed
Similar IDVs
The Indefinite Delivery Contract (IDC) SPE2DR25D1004 was awarded by the Defense Logistics Agency (DLA) Troop Support Medical Supply Chain to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $9,999,999,999, aims to establish a Pharmaceutical Prime Vendor Global Program to provide worldwide pharmaceutical support to various DoD customers, including the Defense Health Agency, U.S. Coast Guard, and U.S. Naval Fleet. The...
The Indefinite Delivery Contract (IDC) SPE2DR25D1102 was awarded by the Defense Logistics Agency (DLA) Troop Support Medical Supply Chain to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $9,999,999,999, covers the delivery of a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. This includes specialty medications, brand-name and generic drugs,...
The Indefinite Delivery Contract (IDC) SPE2DU25D5141 was awarded by the Defense Logistics Agency (DLA) Troop Support Medical Supply Chain to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, to provide worldwide pharmaceutical support to various DoD customers. The $999,999,999 contract has a 30-month base period and three 30-month option periods, totaling an estimated value of $30.3 billion. This IDC aims to establish Pharmaceutical Prime Vendor Global Program Generation V...
The Indefinite Delivery Contract (IDC) SPE2DR25D7910 was awarded by the Defense Logistics Agency (DLA) Troop Support Medical Supply Chain to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $999,999,999, has a period of performance through December 2026 and is intended to provide worldwide pharmaceutical support to various Department of Defense (DoD) customers, including the Defense Health Agency, the U.S. Coast Guard, and...
This Indefinite Delivery Contract (IDC) award, valued at $999,999,999, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The IDC encompasses a broad spectrum of critical medical commodities including...
The Indefinite Delivery Contract (IDC) SPE2DR25D1002, awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, is a single-award contract valued at $9,999,999,999 running through December 31, 2036. This IDC serves as the primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally, including specialty medications, brand-name and generic drugs, vaccines, syringes,...
The Indefinite Delivery Contract (IDC) awarded by the Defense Logistics Agency (DLA) Troop Support Medical Supply Chain to AmerisourceBergen Drug Corp, valued at $999,999,999, covers the delivery of a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract has a 30-month base period and three 30-month option periods, for a total estimated value of $30.3 billion. The IDC serves as the Pharmaceutical Prime Vendor Global...
The Indefinite Delivery Contract (IDC) SPE2DX25D5000 was awarded by the Defense Logistics Agency (DLA) Troop Support Medical Supply Chain, a defense agency, to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has a total ceiling value of $999,999,999 and runs through March 2035. The purpose of this IDC is to establish Pharmaceutical Prime Vendor Global Program Generation V contracts to provide worldwide pharmaceutical support,...
The federal Indefinite Delivery Contract (IDC) SPE2DR25D1109 was awarded by the Defense Logistics Agency (DLA) Troop Support Medical Supply Chain to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The IDC, with a ceiling value of $9,999,999,999, covers a wide range of pharmaceutical and medical products to support various Department of Defense (DoD) customers, the U.S. Coast Guard, and other government agencies globally. This IDC is part of...
The Indefinite Delivery Contract (IDC) SPE2DR25D1116 was awarded by the Defense Logistics Agency (DLA) Troop Support Medical Supply Chain to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $999,999,999 IDC has an ultimate completion date of December 31, 2036 and serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The original...

The Indefinite Delivery Contract (IDC) SPE2DR25D1110 was awarded by the Defense Logistics Agency (DLA) Troop Support Medical Supply Chain to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $9,999,999,999, is an unrestricted, fully competitive acquisition that aims to establish Pharmaceutical Prime Vendor Global Program Generation V contracts to provide worldwide pharmaceutical support to various DoD customers, including the Defense Health Agency, Department of Defense, U.S. Coast Guard, and U.S. Naval Fleet.

The contract covers an extensive array of medical commodities, including specialty medications, brand-name and generic drugs, vaccines, syringes, vials, and test kits across multiple therapeutic domains. It has a 30-month base period and three 30-month option periods, for a total estimated value of $30.3 billion. The contract utilizes a Lowest Price Technically Acceptable (LPTA) acquisition strategy, with the Government intending to make multiple primary supplier awards for separate regions and one award for a backup supplier covering all regions. This diversification is aimed at increasing the Department of Defense's resiliency and access to vital pharmaceuticals during contingencies or natural disasters.

Generated 6/6/25, 9:45 AM